Stevanato Group (NYSE:STVN) Director William Federici Buys 20,000 Shares of Stock

Stevanato Group S.p.A. (NYSE:STVN) Director William Federici acquired 20,000 shares of the company’s stock in a transaction on Monday, November 9th. The stock was acquired at an average cost of €13.72 per share, for a total transaction of €274,400.00. Following the completion of the acquisition, the director owned 46,991 shares of the company’s stock, valued at €644,716.52. This trade represents a 74.10% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Stevanato Group Price Performance

Shares of STVN stock traded up €0.42 during trading hours on Thursday, hitting €14.33. 879,105 shares of the company’s stock were exchanged, compared to its average volume of 563,473. Stevanato Group S.p.A. has a fifty-two week low of €12.05 and a fifty-two week high of €24.01. The firm has a market cap of $4.34 billion, a P/E ratio of 24.70, a P/E/G ratio of 1.40 and a beta of 0.80. The company has a quick ratio of 1.19, a current ratio of 1.73 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average of €19.36 and a two-hundred day moving average of €17.93.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing the consensus estimate of €0.17 by (€0.01). The company had revenue of €326.06 million during the quarter. Stevanato Group had a return on equity of 10.51% and a net margin of 11.24%. Sell-side analysts forecast that Stevanato Group S.p.A. will post 0.67 EPS for the current year.

Analyst Upgrades and Downgrades

STVN has been the topic of several research reports. Weiss Ratings upgraded Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Deutsche Bank initiated coverage on Stevanato Group in a research report on Wednesday, October 7th. They set a “hold” rating for the company. William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 4th. Citigroup decreased their price objective on Stevanato Group from $26.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. Finally, UBS Group lowered their target price on shares of Stevanato Group from $23.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Hedge Funds Weigh In On Stevanato Group

A number of institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC purchased a new stake in Stevanato Group in the 2nd quarter valued at $59,000. State of Wyoming acquired a new position in shares of Stevanato Group during the 3rd quarter valued at about $75,000. Fifth Third Bancorp boosted its position in shares of Stevanato Group by 22.6% during the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after acquiring an additional 773 shares during the last quarter. GW&K Investment Management LLC grew its holdings in shares of Stevanato Group by 118.3% in the third quarter. GW&K Investment Management LLC now owns 6,086 shares of the company’s stock valued at $128,000 after purchasing an additional 3,298 shares during the period. Finally, Ieq Capital LLC purchased a new stake in shares of Stevanato Group in the third quarter valued at about $292,000.

About Stevanato Group

Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.